<DOC>
	<DOCNO>NCT00419887</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , effect vildagliptin body change blood level vildagliptin single multiple oral dos vildagliptin healthy Chinese volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Effect Vildagliptin How Body Changes Blood Level Vildagliptin Healthy Chinese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Chinese healthy volunteer age 18 45 year age include In good health confirm past medical history , physical examination , electrocardiogram , laboratory test urinalysis screen baseline evaluation All subject must parent Chinese origin citizenship must bear China . Body mass index ( BMI ) within range 19 24 kg/m2 weigh least 50 kg Smokers Use prescription drug within four ( 4 ) week prior dose , overthecounter ( OTC ) medication ( vitamin , herbal supplement , dietary supplement ) within two ( 2 ) week prior dose . Paracetamol ( equivalent China ) acceptable Participation clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Donation loss 400 ml blood within 8 week prior first dose , longer required local regulation . Significant illness within two week prior dose . A past personal close family medical history clinically significant cardiac abnormality History Acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease ) Clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) Known hypersensitivity severe adverse event darifenacin similar drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize participation study Immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Drug alcohol abuse within 12 month prior dose . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Safety , tolerability , pharmacokinetics , pharmacodynamics , LAF237 , vildagliptin , Chinese , healthy volunteer</keyword>
</DOC>